Christine Cournoyer Sells 29,136 Shares of CareDx, Inc (NASDAQ:CDNA) Stock

CareDx, Inc (NASDAQ:CDNA) Director Christine Cournoyer sold 29,136 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $15.96, for a total transaction of $465,010.56. Following the sale, the director now directly owns 37,045 shares of the company’s stock, valued at approximately $591,238.20. This represents a 44.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Christine Cournoyer also recently made the following trade(s):

• On Tuesday, May 6th, Christine Cournoyer sold 16,700 shares of CareDx stock. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00.

CareDx Price Performance

Shares of CareDx stock opened at $16.10 on Friday. CareDx, Inc has a fifty-two week low of $12.90 and a fifty-two week high of $34.84. The firm has a fifty day moving average price of $17.64 and a two-hundred day moving average price of $20.97. The company has a market cap of $896.46 million, a PE ratio of -5.96 and a beta of 2.27.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period in the prior year, the firm earned ($0.03) EPS. The business’s revenue was up 17.6% on a year-over-year basis. Analysts expect that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CareDx

A number of hedge funds have recently made changes to their positions in CDNA. Barclays PLC raised its stake in shares of CareDx by 123.8% in the 3rd quarter. Barclays PLC now owns 98,505 shares of the company’s stock valued at $3,075,000 after buying an additional 54,482 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of CareDx by 34.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,474 shares of the company’s stock valued at $1,862,000 after buying an additional 15,238 shares in the last quarter. ARS Investment Partners LLC raised its stake in shares of CareDx by 6.3% in the 4th quarter. ARS Investment Partners LLC now owns 101,968 shares of the company’s stock valued at $2,183,000 after buying an additional 6,083 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of CareDx by 31.0% in the 4th quarter. SG Americas Securities LLC now owns 24,087 shares of the company’s stock valued at $516,000 after buying an additional 5,706 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in shares of CareDx by 6.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 29,107 shares of the company’s stock valued at $623,000 after buying an additional 1,816 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price objective on shares of CareDx in a report on Monday, May 5th. Stephens reaffirmed an “overweight” rating and set a $40.00 price objective on shares of CareDx in a report on Monday, May 5th. The Goldman Sachs Group decreased their price objective on shares of CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Finally, StockNews.com downgraded shares of CareDx from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.